The frequency, treatment and clinical outcomes of stent thrombosis after use of TAXUS™ stent

Korean Circulation Journal

Volumn 37, Issue 12, 2007, Pages 641-646

  Moon, Jae Youn ^a,b   Myung, Ho Jeong ^a,b   In, Soo Kim ^a   Chung, Hwan Jun ^a   Jung, Sun Cho ^a,b   Jong, Won Chung ^a,b   Sim, Doosun ^a,b   Young, Joon Hong ^a,b   Ju, Han Kim ^a,b   Ahn, Youngkeun ^a,b   Jeong, Gwan Cho ^a,b   Jong, Chun Park ^a,b   Jung, Chaee Kang ^a,b  

^a Chonnam National University Medical School   (South Korea)

^b Chonnam National University   (South Korea)

Author keywords

Angina pectoris; Myocardial infarction; Stents; Thrombosis

Indexed keywords

ANTITHROMBOCYTIC AGENT;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANALYTIC METHOD; ANGIOGRAPHY; ARTICLE; CLINICAL ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; INCIDENCE; MALE; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; RETROSPECTIVE STUDY; STENT; STENT THROMBOSIS;

EID: 38949107672     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2007.37.12.641     Document Type: Article

References (30)

1. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-80.
2. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-23.
3. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-31.
4. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymerbased paclitaxel-eluting stents for coronary artery lesions. Circulation 2003; 108: 788-94.
5. Schampaert E, Cohen EA, Schluter M, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004; 43: 1110-5.
6. Schofer J, Schluter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003; 362: 1093-9.
7. Park SJ, Kim YH, Lee BK, et al. Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis: comparison with bare metal stent implantation. J Am Coll Cardiol 2005; 45: 351-6.
8. Jeremies A, Sylvia B, Bridges J, et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 2004; 109: 1930-2.
9. Park DW, Park SW. Stent thrombosis in the era of the drug- eluting stent. Korean Circ J 2005; 35: 791-4.
10. Park S, Hong GR, Seo HS, Tahk SJ. Stent thrombosis after successful drug-eluting stent implantation. Korean Circ J 2005; 35: 163-71.
11. Daemen J, Garcia-Garcia HM, Kukreja N, et al. The long-term value of sirolimus- and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus. Eur Heart J 2007; 28: 26-32.
12. Ellis SG, Colombo A, Grube E, et al. Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3,445 patients followed for up to 3 years. J Am Coll Cardiol 2007; 49: 1043-51.
13. Moreno R, Fernandez C, Hernandez R, et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005; 45: 954-9.
14. Schampaert E, Moses JW, Schofer J, et al. Sirolimus-eluting stents at two years: a pooled analysis of SIRIUS, E-SIRIUS, and C-SIRIUS with emphasis on late revascularizations and stent thromboses. Am J Cardiol 2006; 98: 36-41.
15. Farb A, Boam AB. Stent thrombosis redux: the FDA perspective. N Engl J Med 2007; 356: 984-7.
16. De Luca G, Carbone G, Maione A, Gregorio G. In-stent thrombosis after discontinuation of antiplatelet therapy 2 years after DES implantation: a case report. Int J Cardiol 2007; 116: 399-400.
17. Artang R, Dieter RS. Analysis of 36 reported cases of late thrombosis in drug-eluting stents placed in coronary arteries. Am J Cardiol 2007; 99: 1039-43.
18. Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Catheter Cardiovasc Interv 2007; 69: 334-40.
19. Burzotta F, Romagnoli E, Manzoli A, et al. The Outcome of PCI for stent-ThrombosIs Multicentre Study (OPTIMIST): rationale and design of a multicenter registry. Am Heart J 2007; 153: 377, e1-5.
20. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293: 2126-30.
21. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007; 369: 667-78.
22. Oyabu J, Ueda Y, Ogasawara N, Okada K, Hirayama A, Kodama K. Angioscopic evaluation of neointima coverage: sirolimus drug-eluting stent versus bare metal stent. Am Heart J 2006; 152: 1168-74.
23. Park HW, Jeong MH, Park OY, et al. The long-term clinical effects of heparin coated coronary stent. Korean Circ J 2002; 32: 773-80.
24. Kim W, Jeong MH, Cha KS, et al. The effect of anti-oxidants (carvedilol and probucol) loaded stents in a porcine coronary restenosis model. Circ J 2005; 69: 101-6.
25. Kim W, Jeong MH, Hong YJ, et al. The long-term clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (Abciximab: ReoPro®) coated stent in patients with acute myocardial infarction. Korean Circ J 2004; 34: 1063-9.
26. Hong YJ, Jeong MH, Kim W, et al. Effect of abciximab-coated stent on in-stent intimal hyperplasia in human coronary arteries. Am J Cardiol 2004; 94: 1050-4.
27. Park OY, Jeong MH, Kim JH, et al. The inhibitory effects of a platelet glycoprotein IIb/IIIa receptor blocker-coated stent on neointima formation and inflammatory response in porcine coronary stent restenosis. Korean Circ J 2003; 33: 439-45.
28. Lim SY, Jeong MH. Is heparin-coated stent effective in patients with acute myocardial infarction? Korean Circ J 2004; 34: 537-9.
29. Kim W, Jeong MH, Kim KH, et al. The clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (abciximab-ReoPro)-coated stent in acute myocardial infarction. J Am Coll Cardiol 2006; 47: 933-8.
30. Lim SY, Bae EH, Jeong MH, et al. The effect of oral administration of alpha lipoic acid and alpha lipoic acid coated stent in porcine in-stent restenosis model. Korean Circ J 2006; 36: 495-502.